Articles

Proof of concept

Combination therapy for Renal cancer. Synergistic drug combination containing CI-994, tabacin, erlotinib and dasatinib. Patent filed September 24th 2019, UNIGE licensed by Chimera Bio B.V. in 2022. A total of 10 compounds were included in the study.

Go to the article

Proven activity in vivo, look for effect of mono therapies and select doses for the drug combinations

Shows synergistic anti-cancer effect only combination

Non-toxic

Impairs the division of cancer cells with multipolar (mechanism unknown for those drug when applied individually)

Combining drug allowed the use of apps. 10-fold lower concentrations

Proof of concept

Optimize drug combination (C2): high activity, selectivity towards specific cells (766-O) and synergy (combinatory index, CI)

Read complete article

“…Really love the services provided by this team. Very good collaboration, thanks a lot for your help!…”

Diederik Engbersen